Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (GB:0SGC)
LSE:0SGC
Holding GB:0SGC?
Track your performance easily
0SGC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.24 - $4.68
Previous Close$3.25
Volume9.14K
Average Volume (3M)4.06K
Market Cap
$608.27M
Enterprise Value$481.92M
Total Cash (Recent Filing)$127.79M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Feb 27, 2025EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding189,491,685
10 Day Avg. Volume1,654
30 Day Avg. Volume4,062
Standard Deviation0.16
R-Squared0.06
Alpha0.00311
Financial Highlights & Ratios
Price to Book (P/B)5.91
Price to Sales (P/S)90.22
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue71.48
Enterprise Value/Gross Profit26.57
Enterprise Value/Ebitda-6.46
Forecast
1Y Price Target
$4.75Price Target Upside46.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arbutus Biopharma News
PremiumCompany Announcements
Arbutus Biopharma Highlights Hepatitis B Treatment Advances
PremiumCompany Announcements
Arbutus Biopharma’s Promising cHBV Treatment Results
PremiumCompany Announcements
Arbutus Biopharma’s Trial Boosts Hepatitis B Treatment
PremiumCompany Announcements
Arbutus Biopharma to Present at Jefferies ConferenceBulls Say, Bears Say
Bulls Say
Innovative TreatmentAdding nivolumab to the imdusiran and VTP-300 treatment further reduces HBsAg levels, enhancing the treatment's effectiveness.
Patient SafetyThe combination of imdusiran and interferon was generally safe and well-tolerated, with no serious adverse events related to the treatment.
Therapeutic EfficacyThe IM-PROVE I dataset suggests that a functional cure in HBV is achievable with a finite treatment regimen including imdusiran.
Bears Say
Earnings OutlookNo change to outlook on earnings.
Market CompetitionThe CHB treatment space remains challenging, as evidenced by companies like JNJ and Roche stepping away.
Product DemandSome experts indicate a lack of interest in reintroducing PEG-IFN into the treatment regimen in the U.S.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.90% Insiders
10.20% Mutual Funds
20.14% Other Institutional Investors
57.68% Public Companies and
Individual Investors
0SGC FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest share price was $2.24 and its highest was $4.67 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Currently, no data Available
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on Nov 06, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.006.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -$0.08.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 189,491,680 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went down -0.13%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Saba Capital Management. It holds Arbutus Biopharma Corporation’s shares valued at 3M.
---
Arbutus Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (46.24% Upside)
$4.75 (46.24% Upside)
Blogger Sentiment
Bullish
GB:0SGC Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.24%
12-Months-Change
Fundamentals
Return on Equity
-67.81%
Trailing 12-Months
Asset Growth
-11.47%
Trailing 12-Months
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
0SGC Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong financial positioning and promising clinical trial data for HBV treatments. However, ongoing legal challenges and high operational cash burn present concerns.Read More>---
0SGC Stock 12 Month Forecast
Average Price Target
$4.75
▲(46.24% Upside)
Technical Analysis
Best Analysts Covering 0SGC
1 Year
1 Year Success Rate
13/24 ratings generated profit
1 Year Average Return
+11.41%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +11.41% per trade.
---